A federal class action lawsuit has been filed against Luminary Genetics (formerly NextGen Genetics) in California, alleging that its widely used PGT-A embryo genetic screening test is unreliable. Plaintiffs claim the company aggressively marketed the test as highly accurate for selecting viable embryos during IVF, leading them to discard healthy embryos and abandon pregnancy attempts.
The core accusation revolves around claims that Luminary Genetics misled patients about the accuracy and necessity of their PGT-A test, resulting in the loss of potentially viable embryos and dashed hopes of parenthood.
Multiple fertility patients are involved in the suit, with at least one plaintiff reporting discarding several embryos deemed abnormal by the test, and experiencing no successful pregnancies from embryos that tested as normal. This situation has reportedly led some patients to cease IVF treatment altogether.
Questionable Accuracy and Clinical Impact
The PGT-A (Preimplantation Genetic Testing for Aneuploidy) test, commonly employed in IVF cycles, is facing scrutiny over its effectiveness. Critics and plaintiffs suggest that the test's outcomes may not accurately reflect an embryo's true reproductive potential, with some believing that embryos flagged as abnormal by PGT-A could still be viable.
The necessity of PGT-A is being questioned, with lawsuits asserting a lack of evidence that the test leads to more successful pregnancies. Furthermore, concerns have been raised about the biopsy procedure required for PGT-A, suggesting it may damage blastocysts and impair their viability before implantation.
Read More: Dick Vitale's 5th Cancer Battle: Melanoma Found in Lung and Liver on April 14, 2026
Financial Incentives and Market Practices
Reports indicate that the PGT-A market has seen significant growth, partly due to financial incentives for clinics. Some clinics have been described as practically mandating PGT-A for most patients, with its utilization potentially influencing clinic budgets. This has led to speculation about whether financial motivations might influence clinical decisions regarding the test's application.
While PGT-A testing itself is not alleged to cause miscarriages, its purported unreliability and the subsequent actions taken by patients based on its results are at the center of the legal challenges. The lawsuits suggest that Luminary Genetics, and potentially other companies, have aggressively marketed PGT-A, leading to its widespread adoption despite questions about its scientific foundation and clinical utility.
Background on PGT-A in IVF
PGT-A is a genetic test performed on embryos created during in vitro fertilization (IVF) cycles. Its primary goal is to identify chromosomal abnormalities, such as aneuploidy (an abnormal number of chromosomes), which can affect an embryo's development and implantation. The aim is to help select chromosomally normal embryos for transfer, theoretically increasing the chances of a successful pregnancy and reducing the risk of miscarriage or the birth of a child with a chromosomal condition.
Read More: Palestinian groups sue Australia over arms export documents to Israel
Historically, the use and interpretation of PGT-A results have been subjects of ongoing debate and research within the fertility community. While some clinics and patients find it a valuable tool, others have expressed skepticism about its definitive accuracy and its impact on overall pregnancy success rates.
